ProShare Advisors’s MaxCyte MXCT Stock Holding History
Bought
Maintained
Sold
Other funds holding MXCT
CFM
VP
MA
BFM
CCM
PLC
ProShare Advisors's MXCT Position: Q2 2026 in Review
ProShare Advisors sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 14,660 shares — an estimated $10.3K sold.
ProShare Advisors first reported a position in MXCT in Q1 2022 and held it in 17 quarters. The position peaked at $204K in Q1 2022. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.
- ProShare Advisors reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
- ProShare Advisors sold 14,660 MaxCyte shares in Q2 2026, an estimated $10.3K.
- ProShare Advisors first reported a position in MaxCyte in Q1 2022 and held it in 17 quarters.
- ProShare Advisors's MaxCyte position peaked at $204K in Q1 2022.
- 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.